Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

ClinicalTrials.gov ID: NCT04504279

Public ClinicalTrials.gov record NCT04504279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis. FB-401 will be applied topically for 16 weeks and progress will be assessed by assessment of the skin and patient reports.

Study identification

NCT ID
NCT04504279
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Forte Biosciences, Inc.
Industry
Enrollment
154 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 12, 2020
Primary completion
Jul 13, 2021
Completion
Aug 18, 2021
Last update posted
Sep 15, 2021

2020 – 2021

United States locations

U.S. sites
15
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
First OC Dermatology Fountain Valley California 92708
Center for Dermatology Clinical Research, Inc. Fremont California 94538
Multi-Specialty Research Associates, Inc. Lake City Florida 32055
MedaPhase, Inc. Newnan Georgia 30263
DS Research Clarksville Indiana 47129
The Indiana Clinical Trials Center Plainfield Indiana 46168
DS Research Louisville Kentucky 40241
Lawrence J. Green MD LLC Rockville Maryland 20850
Minnesota Clinical Study Center New Brighton Minnesota 55112
Midwest Children's Health Research Institute Lincoln Nebraska 68516
Dermatology Consulting Services, PLLC High Point North Carolina 27262
Cyn3rgy Research Gresham Oregon 97030
KGL Skin Study Center LLC Newtown Square Pennsylvania 19073
Bellaire Dermatology Associates Bellaire Texas 77401
Texas Dermatology and Laser Specialists San Antonio Texas 78218

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04504279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2021 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04504279 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →